Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage biopharmaceutical company developing therapies for immunology and inflammation diseases, particularly autoimmune conditions. Its lead candidate, obexelimab, is a monoclonal antibody designed to inhibit B-cell activity without depleting B cells; it is being… From the company’s description.
In fiscal 2025, Zenas BioPharma, Inc. reported revenue of $10.00M, up 100.0% from fiscal 2024, and a net loss of $377.74M. Operations used $172.33M in cash. Over the twelve months to Sep 30, 2026, revenue was $11.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zenas BioPharma, Inc. does
In the company’s own words
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage biopharmaceutical company developing therapies for immunology and inflammation diseases, particularly autoimmune conditions. Its lead candidate, obexelimab, is a monoclonal antibody designed to inhibit B-cell activity without depleting B cells; it is being developed for IgG4-related disease, relapsing multiple sclerosis and systemic lupus erythematosus. The company is also advancing orelabrutinib, an oral BTK inhibitor, for progressive multiple sclerosis, along with early-stage candidates targeting IL-17AA/AF and TYK2. Other programs include ZB002 and ZB004, while ZB001 is licensed to a partner for development and commercialization in greater China. Zenas acquires and in-licenses product candidates and may pursue development or commercialization partnerships. It has no products approved for commercial sale and has not generated product sales revenue. The filing describes no reportable business segments or financial scale metrics suitable for inclusion. Its website is www.zenasbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1953926
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zenas BioPharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Zenas BioPharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zenas BioPharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zenas BioPharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zenas BioPharma, Inc.'s last four quarterly filings that the numbers alone won't show?”